Optimistic Outlook for DBV Technologies Amid Promising Viaskin Peanut AdvancementsLast week, we hosted a management dinner with DBV Technologies (Nasdaq: DBVT), where we heard an update on their two parallel programs with the peanut-directed immunotherapy, and 4–7-year-olds. As a reminder, we are quickly approaching the pivotal readout of the Phase 3 VITESSE trial in 4–7-year-olds, where topline data are ancipated by year-end and a planned BLA submission in the first half of next year. Here, we had the opportunity to ask detailed quesons about the VITESSE endpoint, the trial populaon, and key design aspects that improve the PoS versus the historical PEPITES study in 4-11-year-olds.